As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.